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Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed
multigene assay that predicts the risk of distant recurrence in patients with early
breast cancer. Here, we analyzed the concordance of the BCT score with the
Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1,
hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative
breast cancer.
Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed
using the Oncotype DX test were assessed using the GenesWell BCT test. The risk
stratification by the two tests was then compared.
Results: A total of 771 patients from five institutions in Korea were analyzed. According
to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%)
as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were
categorized into the low-, intermediate-, and high-risk groups, respectively, according to
the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated
with advanced lymph node status, whereas no association between RS risk groups and
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nodal status was observed. The concordance between the two risk stratificationmethods
in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups
were combined into one group. However, poor concordance was observed in patients
aged ≤50 years and in those with lymph node-positive breast cancer.
Conclusions: The concordance between the BCT score and RS was low in women
aged≤50 years or with lymph node-positive breast cancer. Further studies are necessary
to identify more accurate tests for predicting prognosis and chemotherapy benefit in
this subpopulation.
Keywords: GenesWell BCT score, oncotype DX recurrence score, concordance, early breast cancer, risk
classification, Asian population
INTRODUCTION
Several multigene expression prognostic assays have been
developed to overcome the limitations of clinical variables such
as tumor size and nodal status for predicting prognosis in
breast cancer (1). These assays are used to predict the risk
of recurrence or distant metastasis after surgery and adjuvant
hormone therapy in hormone receptor-positive early breast
cancer to help treatment decisions regarding chemotherapy.
MammaPrint (2) and Oncotype DX (3) are the first generation
molecular prognostic assays; additional assays such as Prosigna
(4–6) and EndoPredict (7) were developed later.
Oncotype DX (Genomic Health, Redwood City, CA, USA) is
the most widely used multigene assay (3); it uses quantitative
reverse transcription-polymerase chain reaction (qRT-PCR) to
measure the expression of 21 genes in formalin-fixed, paraffin-
embedded (FFPE) tissues. The Oncotype DX recurrence score
(RS) also predicts the benefit of adding chemotherapy to
hormone therapy in estrogen receptor (ER)-positive breast
cancer (8, 9). Moreover, RS results are currently included in
clinical guidelines for treatment decisions in early breast cancer
(10–12). The American Joint Committee on Cancer eighth
edition cancer staging system was recently revised to include this
score for prognosis in breast cancer (13).
However, recent studies showed that other prognostic scores
such as PAM50-based Prosigna risk of recurrence (ROR) score
(6) and EPclin by EndoPredict (14) are more accurate than
Oncotype DX RS for predicting the risk of distant recurrence
in endocrine-treated postmenopausal patients with ER-positive
breast cancer. Comparison of the prognostic value of six
multigene signatures, including Clinical Treatment Score, four
immunohistochemical markers (IHC4), RS, ROR, Breast Cancer
Index (BCI), and EPclin in 774 postmenopausal women with
ER-positive, human epidermal growth factor receptor 2 (HER2)-
negative breast cancer also demonstrated that ROR, BCI, and
EPclin are more prognostic for overall and late distant recurrence
than RS in patients with lymph node-negative breast cancer
(15). However, studies comparing Oncotype DX and other assays
were performed in Western populations, and the results in Asian
patients with breast cancer remain unclear.
Asian breast cancer differs from Western breast cancer in
terms of age-specific incidence rates (16–18). Approximately
half of breast cancer patients (peak age: 45–50 years) are
premenopausal in Asian countries, whereas 15–30% of Western
breast cancer (peak age: 55–60 years) are premenopausal (19–
21). In addition, distinct biological features of Asian breast cancer
include higher prevalence of luminal B subtype, more frequent
TP53 mutation, and more active immune microenvironment,
suggesting the needs for inclusion of more Asian women in
clinical trials to unravel the ethnic difference of breast cancer
(21, 22). However, most genomic algorithms for use in breast
cancer tests are based on postmenopausal women in Western
countries, which raises concerns regarding their prognostic or
predictive value in Asian, or young breast cancer patients.
Notably, recent data from the Trial Assigning Individualized
Options for Treatment (TAILORx) (23) showed that there is no
chemotherapy benefit in patients aged >50 years with hormone
receptor-positive, HER2-negative, lymph node-negative breast
cancer with a RS of 11–25, while those aged ≤50 years with a
RS of 16–25 may benefit from chemotherapy. The trial results
suggested that the predictive value of the RS for chemotherapy
benefit or “number needed to treat (NNT)” can be different in
Asian breast cancer patients, as this population includes a greater
number of patients aged ≤50 years. The absolute risk reduction
(ARR) and NNT for a RS of 21–25 was 6.5 and 15.4, while it was
1.6 and 62.5 for a RS of 16–20 (23), respectively. Meanwhile, the
ARR and NNT for a RS ≥26 was 25.0 and 4.0, respectively (24).
A recent study showed that tailored therapy based on Oncotype
DX results could result in a net cost increase in initial care of
American breast cancer if women aged ≤50 years with tumors
with RS of 16–25 all chose to receive chemotherapy (25).
The GenesWell Breast Cancer Test (BCT) (Gencurix, Inc.,
Seoul, Korea) is a molecular prognostic assay that predicts the
risk of 10–year distant metastasis in patients with pathologic
N0 or N1 status (pN0-N1), hormone receptor-positive, HER2-
negative breast cancer (26). This test is a qRT-PCR-based assay
that measures the relative expression of six prognostic genes
and two clinical variables using FFPE tumor tissues similar
to the Oncotype DX. The ability of this assay to predict the
chemotherapy benefit was also recently demonstrated in Asian
breast cancer patients (27). Here, we aimed to assess the
agreement in risk classification between the BCT score and
the RS in a large sample of Asian breast cancer patients from
multiple institutions.
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MATERIALS AND METHODS
Patients and Tissue Samples
FFPE tumor blocks were obtained from patients meeting the
following criteria: with hormone receptor-positive early breast
cancer, underwent curative resection of the primary tumor at any
of the five institutions (Samsung Medical Center, Asan Medical
Center, Korea University Guro Hospital, Gangnam Severance
Hospital in Seoul, and National Cancer Institute in Gyeonggi-
do) in Korea between 2010 and 2017, and with a reportable
RS. FFPE tumor tissues not eligible for the GenesWell BCT
test or cases without sufficient tumor or clinical information
were excluded. Hormone receptors (ER or progesterone receptor
[PR]) and HER2 status were determined at local laboratories.
The staining of ER or PR by immunohistochemistry (IHC) was
scored using the semi-quantitative Allred score (AS) with a
maximum score of 8, and AS >2 was considered as positive
as described previously (28, 29). HER2 status was measured
using the IHC, fluorescence in situ hybridization (FISH), or
silver-enhanced in situ hybridization (SISH). According to the
American Society of Clinical Oncology/College of American
Pathologists guidelines, HER2 positivity was defined as an
intensity of 3+ by IHC or as gene amplification ratio
of ≥2.0 or average HER2 copy number ≥6 by FISH or
SISH (30).
Oncotype DX and BCT Tests
Samples were delivered to Genomic Health for Oncotype
DX testing prior to the study. Tissue samples were prepared
following the pathology guidelines of Oncotype DX. The RS
results were determined by Genomic Health, as previously
described (3).
Samples previously analyzed using the Oncotype DX test
were used for the GenesWell BCT test. RNA was extracted
from FFPE tissues, and samples containing sufficient residual
RNA were subjected to qRT-PCR as previously described
(26). The BCT score was calculated using two clinical
variables (tumor size and nodal status) in combination
with the relative expression of the six prognostic genes
(UBE2C, TOP2A, RRM2, FOXM1, MKI67, and BTN3A2)
(26). The expression of ESR1, PGR, and ERBB2 was also
quantified relative to the three reference genes (CTBP1, CUL1,
and UBQLN1).
Categorization of Risk Groups
Patients were categorized into BCT high-risk and low-risk groups
according to the BCT scoring criteria reported previously (26).
Briefly, patients with a BCT score <4 were classified as low risk,
and those with a BCT score ≥4 were classified as high risk. For
the Oncotype DX, two different RS ranges were used to classify
patients. First, patients were grouped into low-risk (RS <18),
intermediate-risk (RS 18–30), and high-risk (RS ≥31) groups
using the originally validated cut-off (called clinical cut-off) (3).
Second, patients were classified according to the RS ranges used
in the TAILORx (called TAILORx cut-off) as low-risk (RS <11),
intermediate-risk (RS 11–25), and high-risk (RS ≥26) groups
(24, 31). Clinical risk was determined using the modified version
of Adjuvant! Online as reported in the Microarray in Node-
Negative Disease May Avoid Chemotherapy (MINDACT) trial as
previously described (27).
Statistical Analysis
The association between clinicopathological parameters and the
BCT score or the RS was analyzed using the Chi-square test.
Chi-square test was also used to compare the distribution of
each score between the subgroups. The Jonckheere-Terpstra test
was used to determine trends in the association between gene
expression and risk scores (32, 33). Differences were considered
statistically significant at P < 0.05. All statistical analyses were
performed using R 3.2.0 (http://r-project.org).
RESULTS
Patient Characteristics
The GenesWell BCT test was used to analyze 795 FFPE
tissue samples from patients with pN0-N1, hormone receptor-
positive, HER2-negative breast cancer with available RS results,
and the BCT score was calculated for 771 patients. Sample
availability is described in Supplementary Figure 1. The clinical
characteristics of the patients included in the study are
summarized in Table 1. All patients were Asians. The median
age was 47 years (range, 23–79 years). A total of 66.7% and
33.3% of the patients were aged ≤50 years and >50 years,
respectively. Most of the tumors were ductal carcinoma (85.1%),
pN0 (80.3%), histologic grade 2 or 3 (82.2%), and nuclear grade 2
or 3 (91.8%).
BCT Score-Based Risk Classification
Regarding BCT score distribution, the most common was
3–4 (30.7%), followed by 4–5.5 (27.1%) and 2–3 (22.6%)
(Figure 1A). The BCT score distribution differed significantly
between lymph node-negative and node-positive subgroups
(Figures 1B,C) (P < 0.001). Within each nodal subgroup, the
BCT score distribution was similar between patients aged ≤50
years and those aged >50 years (P = 0.785 for the lymph
node-negative subgroup and P = 0.694 for the node-positive
subgroup) (Figure 2).
In the classification of patients according to the BCT score,
68.4% (n = 527) of patients were included in the BCT low-
risk group, whereas 31.6% (n = 244) were in the BCT high-risk
group (Table 1 and Figure 1A). The proportion of BCT high-
risk patients was higher in the node-positive (53.9%) than that
in the node-negative subgroup (26.1%) (Figures 1B,C). Patients
classified into the BCT high-risk group had significantly larger
tumors (P < 0.001), more advanced pN status (P < 0.001), more
advanced histologic grade (P < 0.001), and higher nuclear grade
(P < 0.001) than those in the BCT low-risk group. No significant
differences in age, PR status and histological type were observed
between the two risk groups (Table 1).
RS-Based Risk Classification
Patients were re-classified as low risk, intermediate risk, and high
risk according to the RS results. The most frequent RS range was
11–15 (27.9%), followed by 18–25 (27.1%) (Figure 1A). The RS
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TABLE 1 | Clinical characteristics of the risk groups according to the BCT score.
BCT score
Characteristics All Low risk (<4) High risk (≥4) P-value
n, % 771 527 68.4% 244 31.6% –
Age (years) 0.940
≤40 135 17.5% 90 66.7% 45 33.3%
40–50 379 49.2% 260 68.6% 119 31.4%
50–60 175 22.7% 122 69.7% 53 30.3%
>60 82 10.6% 55 67.1% 27 32.9%
ER -
Positive 771 100.0% 527 68.4% 244 31.6%
PR 0.470
Negative 78 10.1% 50 64.1% 28 35.9%
Positive 693 89.9% 477 68.8% 216 31.2%
Tumor size (cm) <0.001
≤2.0 504 65.4% 414 82.1% 90 17.9%
>2.0 267 34.6% 113 42.3% 154 57.7%
pN <0.001
0 619 80.3% 457 73.8% 162 26.2%
1 152 19.7% 70 46.1% 82 53.9%
Histologic grade <0.001
1 137 17.8% 120 87.6% 17 12.4%
2 542 70.3% 364 67.2% 178 32.8%
3 92 11.9% 43 46.7% 49 53.3%
Nuclear grade <0.001
1 63 8.2% 55 87.3% 8 12.7%
2 589 76.4% 406 68.9% 183 31.1%
3 119 15.4% 66 55.5% 53 44.5%
Histology 0.606
Ductal 656 85.1% 454 69.2% 202 30.8%
Lobular 67 8.7% 44 65.7% 23 34.3%
Mucinous 18 2.3% 10 55.6% 8 44.4%
Others* 27 3.5% 18 66.7% 9 33.3%
Unknown 3 0.4% 1 33.3% 2 66.7%
*Cribriform, ductal carcinoma with mucinous, tubular, mixed ductal and lobular, papillary, micropapillary, and metaplastic.
BCT, breast cancer test; ER, estrogen receptor; pN, pathologic nodal status; PR, progesterone receptor.
ER and PR status was assessed by immunohistochemistry. P < 0.05 are marked in bold.
distribution was similar between the lymph node-negative and
node-positive subgroups (P = 0.341) (Figures 1B,C). However,
a significant difference in the RS distribution according to
age was observed in each nodal subgroup (P = 0.020 for
the lymph node-negative and P = 0.035 for the node-positive
subgroup) (Figure 2).
Using the original clinical cut-off, 441 (57.2%), 261 (33.9%),
and 69 (8.9%) patients were classified as low risk, intermediate
risk, and high risk, respectively (Supplementary Table 1).
Meanwhile, based on the RS ranges used in TAILORx,
134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were
categorized as low risk, intermediate risk, and high risk,
respectively (Supplementary Table 1). Compared with the risk
classification using the original clinical cut-off, the TAILORx cut-
off categorized more patients as intermediate risk and fewer as
low risk.
The proportion of patients classified into the high-risk group
according to the RS (8.9% using the clinical cut-off and 15.7%
using the TAILORx cut-off) was lower than that of patients
classified according to the BCT score (31.6%). In contrast to
the BCT high-risk group, the RS high-risk group was not
significantly associated with advanced pN status. Negative PR
status was significantly correlated with a high RS (P < 0.001)
(Supplementary Table 1).
Concordance Between the BCT Score and
the RS
The concordance in risk stratification between the BCT score and
the RS was analyzed using the RS ranges of TAILORx. The overall
concordance between the two risk classifications was 71.9% when
the RS low-risk and intermediate-risk groups were combined
into one group (non-high-risk group, RS 0–25) (Table 2). Of
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FIGURE 1 | Distribution of the BCT score and Oncotype DX RS by nodal status. Proportion of patients within each risk score range or risk group in (A) all patients
(n = 771), (B) lymph node-negative (LN-) patients (n = 619), and (C) lymph node-positive (LN+) patients (n = 152).
527 patients in the BCT low-risk group, 480 (91.9%) were
classified as non-high risk according to the RS. Subgroup analysis
according to nodal status showed that the concordance between
the two scores was different in the lymph node-negative and
node-positive subgroups. The overall concordance was higher
in the lymph node-negative subgroup (76.6%) than that in the
node-positive subgroup (52.6%) (Table 2).
We also assessed the concordance between the two scores
according to age: ≤50 years and >50 years. Based on recent
findings on the benefits of chemotherapy for patients with a
RS midrange score (11–25) from TAILORx (23), patients were
categorized into chemobenefit and non-chemobenefit groups
using different RS ranges for each age subgroup. In patients
aged ≤50 years, those with RS 0–15 and RS ≥16 were
categorized into non-chemobenefit and chemobenefit groups,
respectively, whereas in patients aged >50 years, the RS
ranges used for the classification into non-chemobenefit and
chemobenefit groups were RS 0–25 and RS ≥26, respectively.
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FIGURE 2 | Distribution of the BCT score and Oncotype DX RS by age within each nodal subgroup. Proportion of patients within each risk score range according to
age and nodal status. (A) Patients aged ≤50 years with lymph node-negative (LN-) breast cancer (n = 410). (B) Patients aged >50 years with lymph node-negative
(LN-) breast cancer (n = 209). (C) Patients aged ≤50 years with lymph node-positive (LN+) breast cancer (n = 104). (D) Patients aged >50 years with lymph
node-positive (LN+) breast cancer (n = 48).
The overall concordance was higher in women aged >50
years (72.8%) than in those aged ≤50 years (52.9%) (Table 2).
However, in each nodal subgroup, the concordance results
differed between patients aged ≤50 years and those aged >50
years. In patients with lymph node-negative breast cancer,
the concordance was higher in those aged >50 years (77.5%)
than in those ≤50 years (53.2%) (Table 2). By contrast, in the
lymph node-positive subgroup, the concordance was similar
between patients aged >50 years (52.1%), and≤50 years (51.9%)
(Table 2). The highest concordance between the two scores was
observed in patients aged >50 years with lymph node-negative
breast cancer.
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TABLE 2 | Concordance in risk stratification between the BCT score and Oncotype DX RS according to nodal status and age.
All
(n = 771)
Lymph node-negative
(n = 619)
Lymph node-positive
(n = 152)
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
n (%) Non-high
risk (0–25)
High risk
(≥26)
Total Non-high
risk (0–25)
High risk
(≥26)
Total Non-high
risk (0–25)
High risk
(≥26)
Total
BCT score Low risk (<4) 480
(62.3%)
47
(6.1%)
527
(68.4%)
414
(66.9%)
43
(6.9%)
457
(73.8%)
66
(43.4%)
4
(2.6%)
70
(46.1%)
High risk (≥4) 170
(22.0%)
74
(9.6%)
244
(31.6%)
102
(16.5%)
60
(9.7%)
162
(26.2%)
68
(44.7%)
14
(9.2%)
82
(53.9%)
Total 650
(84.3%)
121
(15.7%)
771
(100.0%)
516
(83.4%)
103
(16.6%)
619
(100.0%)
134
(88.2%)
18
(11.8%)
152
(100.0%)
≤50 YEARS
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
n (%) Non-
chemobenefit
(0–15)
Chemobenefit
(≥16)
Total Non-
chemobenefit
(0–15)
Chemobenefit
(≥16)
Total Non-
chemobenefit
(0–15)
Chemobenefit
(≥16)
Total
BCT score Low risk (<4) 168
(32.7%)
182
(35.4%)
350
(68.1%)
143
(34.9%)
156
(38.0%)
299
(72.9%)
25
(24.0%)
26
(25.0%)
51
(49.0%)
High risk (≥4) 60
(11.7%)
104
(20.2%)
164
(31.9%)
36
(8.8%)
75
(18.3%)
111
(27.1%)
24
(23.1%)
29
(27.9%)
53
(51.0%)
Total 228
(44.4%)
286
(55.6%)
514
(100.0%)
179
(43.7%)
231
(56.3%)
410
(100.0%)
49
(47.1%)
55
(52.9%)
104
(100.0%)
>50 YEARS
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
Oncotype DX RS
(TAILORx cut-off)
n (%) Non-
chemobenefit
(0–25)
Chemobenefit
(≥26)
Total Non-
chemobenefit
(0–25)
Chemobenefit
(≥26)
Total Non-
chemobenefit
(0–25)
Chemobenefit
(≥26)
Total
BCT score Low risk (<4) 159
(61.9%)
18
(7.0%)
177
(68.9%)
140
(67.0%)
18
(8.6%)
158
(75.6%)
19
(39.6%)
0
(0.0%)
19
(39.6%)
High risk (≥4) 52
(20.2%)
28
(10.9%)
80
(31.1%)
29
(13.9%)
22
(10.5%)
51
(24.4%)
23
(47.9%)
6
(12.5%)
29
(60.4%)
Total 211
(82.1%)
46
(17.9%)
257
(100.0%)
169
(80.9%)
40
(19.1%)
209
(100.0%)
42
(87.5%)
6
(12.5%)
48
(100.0%)
BCT, Breast Cancer Test; RS, recurrence score; TAILORx, Trial Assigning Individualized Options for Treatment.
Comparison of Clinical Risk by Modified
Adjuvant! Online With the BCT Score and
the RS
The clinical risk of patients was examined using the modified
Adjuvant! Online, and the clinical risk classification was
compared with that obtained using the BCT score or the RS.
Overall, 409 (53.0%), and 362 (47.0%) patients were categorized
as clinical low risk and high risk, respectively (Figure 3A).
Among patients in the clinical low-risk group, 11.5 and 9.8%
were categorized as BCT high risk and RS high risk (≥26),
respectively. Among patients in the clinical high-risk group,
45.6% and 77.6% were classified as BCT low risk and RS
non-high risk (0–25), respectively. The clinical risk classification
according to nodal status was different. The proportion of
patients categorized as clinical high risk was higher in the lymph
node-positive subgroup (85.5%) than that in the node-negative
subgroup (37.5%) (Figures 3B,C). The difference between the
clinical risk and the risk stratification using the two tests was
greater in the lymph node-positive subgroup than that in the
node-negative subgroup.
Of note, a recent secondary analysis of TAILORx trial on
the integration of clinical risk to RS showed that the RS ranges
predicting chemotherapy benefit are different in young women
aged ≤50 years according to clinical risk (34). Clinical low-risk
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FIGURE 3 | Comparison of clinical risk with the risk classification by the BCT score or Oncotype DX RS. Proportion of patients within each risk group according to
clinical risk assessment, BCT score, or RS in (A) all patients (n = 771), (B) lymph node-negative (LN-) patients (n = 619), and (C) lymph node-positive (LN+) patients
(n = 152). Clinical risk was determined using the modified Adjuvant! Online, as reported in the MINDACT trial. Risk classification by the RS was based on the
recurrence score ranges used in the TAILORx.
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patients with RS 0–20 and RS ≥21 were categorized into non-
chemobenefit and chemobenefit groups, whereas in clinical high-
risk group, the RS ranges used for the classification into non-
chemobenefit and chemobenefit groups were RS 0–15 and RS
≥16, respectively. Based on these findings, we further assessed the
concordance between the BCT score and the RS in young patients
aged ≤50 years. The overall concordance between the two risk
classifications was 66.3% (341/514) and a higher concordance was
observed in lymph node-negative subgroup (69.3% [284/410])
than node-positive subgroup (54.8% [57/104]) (Table 3).
Figure 4 shows the discordant results between the clinical
risk and the risk classification using the two tests according
to age within each nodal subgroup. In both nodal subgroups,
the proportion of patients with discordant results between the
clinical risk and risk by BCT score (i.e., either clinical low
risk and BCT high risk or clinical high risk and BCT low
risk) according to age was similar. By contrast, there was a
difference in the proportion of patients with discordant results
between the clinical risk and RS risk (i.e., either clinical low
risk and RS chemobenefit or clinical high risk and RS non-
chemobenefit) according to age. The RS categorized a higher
proportion of patients into the chemobenefit group among
clinical low-risk patients aged ≤50 years (21.2% [55/259] in the
lymph node-negative subgroup and 12.5% [2/16] in the node-
positive subgroup) than among those aged >50 years (10.2%
[13/128] in the lymph node-negative subgroup and 0% [0/6]
in the node-positive subgroup). Meanwhile, the proportion of
RS non-chemobenefit patients among clinical high-risk patients
was higher in women aged >50 years (66.7% [54/81] in the
lymph node-negative subgroup and 85.7% [36/42] in the node-
positive subgroup) than in those aged≤50 years (37.7% [57/151]
in the lymph node-negative subgroup and 43.2% [38/88] in the
node-positive subgroup).
The risk stratification using the two tests in clinical high-
or low-risk patients was different in specific subpopulations.
In patients aged ≤50 years within the lymph node-negative
subgroup (n = 259), 21.2% of clinical low-risk patients were
categorized into the chemobenefit group according to the RS,
whereas 12.7% of patients were categorized as BCT high risk
(Figure 4A). Among clinical high-risk patients aged>50 years in
the lymph node-positive subgroup (n= 42), 33.3 and 85.7% were
classified as BCT low risk and non-chemobenefit, respectively,
according to the RS (Figure 4D).
The prognostic value of the two scores was difficult to
compare because of the short follow-up period. However, seven
patients developed distant metastasis after surgery during the
follow-up period in the present study. Both the BCT score
and the RS categorized four of these patients as high risk
(Supplementary Table 2).
Correlation of ER/PR/HER2 Expression
With the BCT Score
The association of the two scores with the gene expression
of ESR1, PGR, and ERBB2 was assessed. Consistent with the
RS algorithm including ESR1 and PGR expression, there was
a statistically significant trend toward lower ESR1 and PGR TA
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FIGURE 4 | Comparison of clinical risk with the risk classification by the BCT score or Oncotype DX RS by age within each nodal subgroup. Proportion of patients
within each risk group according to clinical risk assessment, BCT score, or RS according to age and nodal status. (A) Patients aged ≤50 years with lymph
node-negative (LN-) breast cancer (n = 410). (B) Patients aged >50 years with lymph node-negative (LN-) breast cancer (n = 209). (C) Patients aged ≤50 years with
lymph node-positive (LN+) breast cancer (n = 104). (D) Patients aged >50 years with lymph node-positive (LN+) breast cancer (n = 48). Clinical risk was determined
using the modified Adjuvant! Online as reported in the MINDACT trial. Patients were divided into non-chemobenefit and chemobenefit groups by different RS ranges
according to age group.
expression among patients with a higher RS (Jonckheere-
Terpstra test, P < 0.001) (Figure 5A). Similarly, PGR expression
showed a decreasing trend in correlation with the BCT score
(P = 0.046) (Figure 5B). However, ESR1 expression increased as
the BCT score increased (P < 0.001). ERBB2 expression showed
a decreasing trend as the RS increased (P = 0.029), whereas
no significant association between ERBB2 expression and the
BCT score was observed. We also evaluated the correlation of
the two scores with ER and PR expression by IHC. Negative
correlation of ER (P = 0.002), and PR expression (P < 0.001)
with the RS was observed (Figure 5C). There was no significant
association between ER expression and the BCT score, whereas
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FIGURE 5 | Association between ER, PR, and HER2 expression and the BCT score or Oncotype DX RS. (A) Association of ESR1, PGR, and ERBB2 gene expression
with the RS and (B) the BCT score. (C) Correlation of ER and PR expression by Allred score with the RS and (D) the BCT score. The P-value of the trend was
determined using the Jonckheere-Terpstra test (one-sided). The expression of ESR1, PGR, and ERBB2 was measured by qRT-PCR. ER and PR Allred score were
determined using immunohistochemistry.
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BCT score showed a negative correlation with PR expression
(P = 0.002) (Figure 5D).
Correlation of the RS With BCT Prognostic
Genes
The correlation between the expression of six prognostic genes
included in the BCT score and the RS was also examined. There
was a statistically significant trend toward a higher expression of
five proliferation-related genes (UBE2C,TOP2A,RRM2, FOXM1,
and MK167) among patients with a higher RS (Jonckheere-
Terpstra test, P < 0.001) (Supplementary Figure 2). Although
the expression of the immune response-related gene
BTN3A2 was negatively associated with the BCT score,
it showed an increasing trend in correlation with the
RS (P = 0.027).
DISCUSSION
The present study is the first to compare the BCT score and
the RS for the risk classification of Asian patients with pN0-N1,
hormone receptor-positive, HER2-negative breast cancer. The
study is notable because of the inclusion of a large population of
Asian patients from several institutions.
The present results showed a moderate concordance of 71.9%
between the two scores for risk stratification using the RS ranges
reported in TAILORx. The discrepancy in the risk classification
between the BCT score and RS may be attributable to the
different gene sets and algorithms used to calculate the score.
Moreover, the BCT score algorithm includes clinical factors
(tumor size and nodal status), which are not included in the
RS. When compared the RS risk group distribution in this
study with previous studies, similar distribution was observed.
In the present study, 105 (17.0%), 411 (66.4%), and 103 (16.6%)
patients were classified as low risk, intermediate risk, and high
risk in lymph node-negative subgroup using TAILORx cut-off
(Supplementary Table 1), which are similar to results from a
TAILORx trial (low risk, 16.7%; intermediate risk, 69.0%, and
high risk,14.3%) (23). RS pooled risk group distribution from
several studies was: low risk, 52.6%; intermediate risk, 35.9%,
and high risk, 11.5%, respectively, when RS risk groups were
defined using the original clinical cut-off (35). These results are
also similar to our findings.
The results showed that the agreement between the BCT
score and the RS differed according to nodal status and age.
Better concordance was found in the lymph node-negative
subgroup than in the node-positive subgroup and in patients
aged >50 years than in those ≤50 years. Accordingly, the
highest concordance between the two scores for risk classification
was observed in patients aged >50 years with lymph node-
negative breast cancer. This was related to the differences in
risk assignment by the BCT score or the RS according to nodal
status or age. The poor concordance in the lymph node-positive
subgroup may be associated with the different risk assignment
by the BCT score between the two subgroups. The proportion of
patients classified as high risk according to the BCT was higher in
lymph node-positive than that in node-negative patients, whereas
the RS yielded a similar pattern of risk assignment between the
two subgroups. Given that advanced nodal status is a strong
unfavorable prognostic factor (36, 37), it is not surprising that the
proportion of patients categorized as BCT high risk was higher
in the lymph node-positive subgroup than that in the node-
negative subgroup. By contrast, the distribution of RS ranges
differed between the two age subgroups, whereas the BCT score
distribution was similar in each age subgroup. This may explain
the large difference in risk stratification by the two risk scores in
women aged≤50 years.
Following the previous TAILORx results, a recent secondary
analysis of TAILORx trial further found that clinical risk
stratification provided additional prognostic information to
hormone receptor-positive, HER2-negative, lymph node-
negative breast cancer patients aged ≤50 years with RS 16–25
(34). Importantly, the study showed that there was no benefit
from chemotherapy for women aged ≤50 years with RS 16–20
and at clinical low risk, whereas patients with RS 16–25 and
at clinical high risk do benefit from chemotherapy. Based on
these results, we categorized patients aged ≤50 years into
non-chemobenefit and chemobenefit groups using different
RS ranges according to clinical risk. Patients with RS 0–20
and RS ≥21 were categorized into non-chemobenefit and
chemobenefit groups in clinical low-risk group, whereas in the
clinical high-risk group, the RS ranges used for the classification
of non-chemobenefit and chemobenefit groups were RS 0−15
and RS ≥16, respectively and we assessed the concordance in
risk stratification between the two tests. Similar to the agreement
between the two risk classifications not considering clinical risk,
the concordance in patients aged ≤50 years was lower than that
in patients aged >50 years. The agreement between clinical risk
and risk stratification using the two tests varied depending on
age. In the subgroup analysis by age in each nodal subgroup,
the proportion of patients with discordant results between
clinical risk and RS risk was different between patients aged
≤50 years and those >50 years. The risk stratification using the
two tests in clinical high- or low-risk patients was different in
specific subpopulations including patients aged ≤50 years with
lymph node-negative breast cancer and patients aged >50 years
with lymph node-positive breast cancer. These results raised a
question regarding which risk stratification is more appropriate
in these subpopulations. Moreover, these results suggest the
need for further studies to identify more accurate risk score for
predicting the risk of recurrence or chemotherapy benefit in
Asian breast cancer patients aged ≤50 years.
Because the clinical data was based on a short follow-up
period, a direct comparison of the prognostic and predictive
values of the BCT score with the RS was not possible in this
study. Therefore, the results are not sufficient to determine
which test is more accurate for predicting the risk of recurrence
or chemotherapy benefit in hormone receptor-positive, HER2-
negative early breast cancer. However, the BCT high-risk
group was significantly associated with larger tumor size and
advanced nodal status, whereas the RS showed no significant
relationship with nodal status. Moreover, in a recent study that
compared the prognostic value of six multigene signatures in
postmenopausal patients with ER-positive, HER2-negative breast
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cancer, combined genomic and clinical models such as ROR and
EPclin were more prognostic for late distant recurrence than
other molecular signatures in lymph node-positive patients (15).
These findings suggest that the BCT score based on combined
gene expression and clinical variables, is likely to have a better
prognostic value than RS in lymph node-positive patients.
CONCLUSIONS
The present results showed a moderate accordance in risk
assignment between the two scores, whereas the concordance
was lower in patients aged ≤50 years or those with lymph node-
positive disease. Further studies are necessary to directly compare
the prognostic and predictive values of the two tests in Asian
breast cancer patients aged ≤50 years.
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